(S029) Dosimetric Comparison Between Vaginal Balloons and Rectal Retractors in Intracavitary Brachytherapy

Publication
Article
OncologyOncology Vol 30 No 4_Suppl_1
Volume 30
Issue 4_Suppl_1

There is no significant difference between D2cc%, D1cc%, and D0.1cc% to the rectum and sigmoid colon for VBs and RRs. There was a significant difference in ICRU% rectal point dose between VBs and RRs, but differences in clinical outcome, if present, will require additional investigation.

Richard Pearlman, James Galle, MD, Huisi Ai, PhD, John Cox, MD; University of South Alabama College of Medicine; Indiana University School of Medicine

PURPOSE: Brachytherapy is required for dose escalation in gynecologic cancers to facilitate definitive treatment while attempting to spare nearby organs at risk (OARs). To decrease dose to these OARs, different devices and techniques have been utilized to increase the distance between the source and respective OAR. Traditionally, gauze has been utilized to decrease dose to the rectum. More recently, vaginal balloons (VBs) and rectal retractors (RRs) have been demonstrated as alternative methods. To date, rectal dosimetric comparisons have only been made between gauze packing and either VBs or RRs. The purpose of our study was to compare rectal dosimetry between VBs and RRs.

METHODS: We reviewed brachytherapy plans for 73 implants (tandem and ovoid) in 27 consecutive patients. A VB or an RR was used for posterior displacement of the rectum. Rectal and sigmoid doses were calculated as a percentage of each fraction’s prescription dose.

RESULTS: Rectal D2cc%, D1cc%, and D0.1cc% were 40% ± 12% (VB) and 43% ± 13% (RR) (P = .28); 46% ± 16% (VB) and 46% ± 12% (RR) (P = .75); and 52% ± 18% (VB) and 53% ± 13% (RR) (P = .65), respectively. Sigmoid D2cc%, D1cc%, and D0.1cc% were 67% ± 13% (VB) and 62% ± 14% (RR) (P = .13); 72% ± 16% (VB) and 72% ± 20% (RR) (P = .90); and 89% ± 21% (VB) and 86% ± 23% (RR) (P = .51), respectively. International Commission of Radiation Units and Measurements percent (ICRU%) rectal point doses were 46% ± 17% (VB) and 59% ± 9% (RR) (P = .0001).

CONCLUSION: There is no significant difference between D2cc%, D1cc%, and D0.1cc% to the rectum and sigmoid colon for VBs and RRs. There was a significant difference in ICRU% rectal point dose between VBs and RRs, but differences in clinical outcome, if present, will require additional investigation.

Proceedings of the 98th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(S002) A 15-Year Review of Radiation Therapy for Keloids at Two Institutions
(S003) Single-Fraction Radiation Therapy for the Treatment of Multiple Myeloma Bony Metastases Provides Pain Control and Decreases Time to Chemotherapy
(S001) Prognostic Value of Pretreatment Serum Inflammatory Markers in Patients Receiving Radiation Therapy for Oropharyngeal Cancer
(S004) Trend in Second Malignancy Risk for Head and Neck Cancer With Increased Utilization of IMRT: Analysis of SEER Database
(S005) Comparison of Legal Needs of a Group of Patients With Cancer: Economic and Geographic Factors
(S006) Mission Improvement: Lessons From Initiating a Resident-Led Quality Improvement Project on Smoking Cessation at a County Hospital
(S007) Results of a Phase II Trial Using Cetuximab Plus Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma
(S008) The Effect of Simulation and Treatment Delays for Patients With Oropharyngeal Cancer Receiving Definitive Radiation Therapy in the Era of Risk Stratification Using Smoking and Human Papilloma Virus Status
(S009) Intensity-Modulated Radiation Therapy With Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on Three-Year Toxicity
(S011) Comparative Study Between Ileal Conduit and Indiana Pouch After Cystectomy for Patients With Carcinoma of Urinary Bladder
(S010) Computed Tomography–Assessed Measures of Bone Mineral Density and Muscle Mass as Predictors of Survival in Men With Prostate Cancer
(S012) Quantitative Imaging to Evaluate the Malignant Potential of Pancreatic Cysts
(S013) Spine Stereotactic Radiosurgery With Concurrent Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
(S014) The Impact of Radiation Therapy on Survival in Surgically Resected, High-Risk Patients With Ampullary Adenocarcinoma: A Population-Based Analysis
(S016) The Impact of Stereotactic Body Radiation Therapy on Overall Survival in Patients With Locally Advanced Pancreatic Cancer
Recent Videos
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
Although accuracy remains a focus in whole-body MRI testing in patients with Li-Fraumeni syndrome, comfortable testing experiences may ease anxiety.
Subsequent testing among patients in a prospective study may affirm the ability of cfDNA sequencing to detect cancers in those with Li-Fraumeni syndrome.
cfDNA sequencing may allow for more accessible, frequent, and sensitive testing compared with standard surveillance in Li-Fraumeni syndrome.
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
Related Content